Abstract
ICI 182,780 (Fulvestrant™) is the first in a new class of novel, steroidal, ’pure‘ antioestrogens – the oestrogen receptor (ER) down-regulators. Its unique mode of action and the absence of partial agonist activity make it a candidate for the treatment of advanced breast cancer in both pre- and postmenopausal women. Tamoxifen has been available for use over the past 25 years. However, its partial agonist activity has been associated with detrimental effects, particularly on the endometrium, and may be associated with the development of tamoxifen resistance. Other antioestrogen agents have previously been unable to demonstrate clinically relevant activity following the development of resistance to tamoxifen. In contrast, the unique mechanism of action of ICI 182,780 results in significant clinical activity in patients failing on tamoxifen therapy. Indeed, phase III clinical trials have demonstrated that ICI 182,780 is at least as effective as the aromatase inhibitor anastrozole in the treatment of postmenopausal patients with advanced disease who have progressed during threatment with prior enocrine therapy. As such, ICI 182,780 will provide a valuable addition to the armamentarium for the treatment of advanced breast cancer. © 2001 Cancer Research Society
Keywords: ICI 182,780; anastrozole; tamoxifen; antioestrogens; advanced breast cancer; adjuvant therapy
Full Text
The Full Text of this article is available as a PDF (46.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Assikis V. J., Jordan V. C. Gynecologic effects of tamoxifen and the association with endometrial carcinoma. Int J Gynaecol Obstet. 1995 Jun;49(3):241–257. doi: 10.1016/0020-7292(95)02387-r. [DOI] [PubMed] [Google Scholar]
- Coopman P., Garcia M., Brünner N., Derocq D., Clarke R., Rochefort H. Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast-cancer cells. Int J Cancer. 1994 Jan 15;56(2):295–300. doi: 10.1002/ijc.2910560225. [DOI] [PubMed] [Google Scholar]
- Fisher B., Costantino J. P., Wickerham D. L., Redmond C. K., Kavanah M., Cronin W. M., Vogel V., Robidoux A., Dimitrov N., Atkins J. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998 Sep 16;90(18):1371–1388. doi: 10.1093/jnci/90.18.1371. [DOI] [PubMed] [Google Scholar]
- Howell A., DeFriend D., Robertson J., Blamey R., Walton P. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet. 1995 Jan 7;345(8941):29–30. doi: 10.1016/s0140-6736(95)91156-1. [DOI] [PubMed] [Google Scholar]
- Howell A., Osborne C. K., Morris C., Wakeling A. E. ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer. 2000 Aug 15;89(4):817–825. doi: 10.1002/1097-0142(20000815)89:4<817::aid-cncr14>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
- Osborne C. K., Coronado-Heinsohn E. B., Hilsenbeck S. G., McCue B. L., Wakeling A. E., McClelland R. A., Manning D. L., Nicholson R. I. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst. 1995 May 17;87(10):746–750. doi: 10.1093/jnci/87.10.746. [DOI] [PubMed] [Google Scholar]
- Osborne C. K., Jarman M., McCague R., Coronado E. B., Hilsenbeck S. G., Wakeling A. E. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol. 1994;34(2):89–95. doi: 10.1007/BF00685924. [DOI] [PubMed] [Google Scholar]
- Plotkin D., Lechner J. J., Jung W. E., Rosen P. J. Tamoxifen flare in advanced breast cancer. JAMA. 1978 Dec 8;240(24):2644–2646. [PubMed] [Google Scholar]
- Wade G. N., Blaustein J. D., Gray J. M., Meredith J. M. ICI 182,780: a pure antiestrogen that affects behaviors and energy balance in rats without acting in the brain. Am J Physiol. 1993 Dec;265(6 Pt 2):R1392–R1398. doi: 10.1152/ajpregu.1993.265.6.R1392. [DOI] [PubMed] [Google Scholar]
- Wakeling A. E., Dukes M., Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991 Aug 1;51(15):3867–3873. [PubMed] [Google Scholar]
- Wakeling A. E. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer. 2000 Mar;7(1):17–28. doi: 10.1677/erc.0.0070017. [DOI] [PubMed] [Google Scholar]
- Wakeling A. E. Use of pure antioestrogens to elucidate the mode of action of oestrogens. Biochem Pharmacol. 1995 May 26;49(11):1545–1549. doi: 10.1016/0006-2952(94)00528-t. [DOI] [PubMed] [Google Scholar]